The Metabolomics and Analytics Centre (MAC) at the Leiden Academic Centre for Drug Research (LACDR) at Leiden University will conduct metabolomics and lipidomics measurements of blood samples to develop metabolic and lipidomic biomarkers to diagnose MALSD and MASH. For the metabolomics and lipidomics MAC is using innovative technologies combined with advanced mass spectrometric methods and using automated sample preparation and robotics. MAC is miniaturizing the analytical methods to analyse liver-derived extracellular vesicles and samples obtained from the organ-on-a-chip model, even down to individual cells.

The 26-million-euro project will address the unmet public health need of reducing disease burden
and comorbidities associated with MASLD by designing and optimizing a sustainable and scalable
GRIPonMASH diagnostic platform.
The platform will provide:

• Screening, diagnosis, management and long-term follow-up of MASH high-risk patients to
  ensure early detection
• Development of decision support tools and testing of existing and novel biomarkers for the
  detection of MASH patients through artificial intelligence-based decision support tools
• Development of non-invasive alternatives to diagnostic liver biopsies
• Assessment and personalization of lifestyle advice based on factors like physical activity, diet,
  sleep, smoking, alcohol consumption, and perception of stress

More about the project can be found here: https://griponmash.eu/